Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1895MR)

This product GTTS-WQ1895MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Cervical Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1895MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11624MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ6684MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ4160MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ1981MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ9118MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ9142MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ7379MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ3738MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW